e-resolutions

Resolutions voted on electronically by members of the Unitaid Executive Board

2024

R11-2024-e Acceptance of a Specified Contribution from the European Commission and expansion of investments in new tools to reduce maternal mortality

R10-2024-e “East Africa Program on Oxygen Access (EAPOA)”

R9-2024-e Cost Extension for the Project “Global long-acting drug combination development” (GLAD)

R8-2024-e Cost Extension for the Project “Long-acting pipeline to establish medicines for malaria, tuberculosis and hepatitis C virus with infrastructure for sustainable translational capacity (LONGEVITY)”

R7-2024-e Cost Extension for the Project “Long-acting injectable formulation of ivermectin as a new vector control tool to reduce malaria transmission” (IMPACT)

R6-2024-e Go-ahead for the development of grant agreement packages on Mitigating Antimalarial Drug Resistance for proposed project with Jhpiego Corporation

R5-2024-e Go-ahead for the development of grant agreement packages on Catalyzing Adoption of an Expanded Vector Control Toolbox to Fight Malaria for proposed projects with Swiss Tropical and Public Health Institute, and Centre for Research in Infectious Diseases, Cameroon

R4-2024-e Improved Access to AHD Care and Treatment 4HIV (IMPAACT4HIV) Project

R3-2024-e Transforming Advanced HIV Disease care in LMICs through comprehensive and equitable access (“THRIVE”) Project

R2-2024-e Cost Extension for the Project “Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women”

R1-2024-e Cost Extension for the Project “Advancing Spatial Repellents for Vector-borne Disease Control” (AEGIS)

2023

R23-2023-e Calendar of Board and Committee meetings for 2024

R22-2023-e Enabling Access – Medical Innovations For All

R21-2023-e Mobilizing for Equitable Access

R20-2023-e The Solidarity Project

R19-2023-e Cost Extension for the Project “Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy (SUCCESS)”

R18-2023-e Additional contribution from the Republic of Korea

R17-2023-e Cost Extension for the Project “Adherence Support Coalition to End TB” (ASCENT)

R16-2023-e Cost Extension for the Project “Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs”

R15-2023-e Cost Extension for the Project “Unitaid support to WHO prequalification of medicines and in vitro diagnostics, and to the WHO collaborative procedure for registration”

R14-2023-e Cost Extension for the Project “Broad One Health Endectocide-based Malaria Intervention in Africa” (BOHEMIA)

R13-2023-e Extension for the Project “Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs”

R12-2023-e Additional funding for the Project ‘Late-Stage Development and Regulatory Approval of the Vayu bCPAP and Low-Flow Blender Circuit Devices’

R11-2023-e Additional ACT-A investment for the Project “Tools for Integrated Management of Childhood Illness – TIMCI”

R10-2023-e No-cost extension for COVID-19 Output in the project entitled “Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs”

R9-2023-e Additional ACT-A investments to accelerate and expand Unitaid’s support for the development and introduction of molecular diagnostics

R8-2023-e Extension of authorization to procure COVID-19 therapeutics, with reallocation of unspent ACT-A funds to Unitaid’s Medical Oxygen

R7-2023-e Governance Working Group Appointment of members

R5-2023-e Cost Extension for the Project ‘Preventing deaths from cervical cancer by catalysing the use of optimal screening tests and treatment devices’

R4-2023-e Go-ahead for the development of grant agreement packages on Preventing deaths among adults and children by simplifying Advanced HIV Disease management for proposed projects with Clinton Health Access Initiative (CHAI) and The Aurum Institute

R3-2023-e Governance Working Group Appointment of Chair and Vice-Chair

R2-2023-e Additional contribution from Canada

R1-2023-e Contribution from Portugal

2022

R24-2022-e Amendment to WHO Enabler Grant

R23-2022-e Extension of investments in Unitaid’s COVID-19 Test-and-Treat and Medical Oxygen Portfolios

R22-2022-e HCV Combination Prevention in PWID and Prisoners Project (HEPC3P)

R21-2022-e Catalyse uptake of Under-utilised Tools & Treatment Simplification for HEPC (CUTTS HEPC)

R20-2022-e Innovate, Involve, Inspire: Preventing Hepatitis C Through Community-Led Harm Reduction

R19-2022-e: Calendar of Board and Committee meetings for 2023

R18-2022-e: Amended Calendar of Board and Committee meetings for 2022

R17-2022-e: Better Evidence and Formulations for Improved MDR-TB Treatment for children (BENEFIT Kids)

R16-2022-e: Accelerating tools to drive tuberculosis detection (DriveDx4TB)

R15-2022-e: START 4-ALL”, implemented by Liverpool School of Tropical Medicine (LSHTM)

R14-2022-e: Research to expand access to Heat-Stable Carbetocin for the treatment of Postpartum Haemorrhage

R13-2022-e: TRANSFORM: Increasing equitable access to tranexamic acid to reduce deaths from postpartum haemorrhage Project

R12-2022-e: AMPLI-PPHI: Accelerating Measurable Progress and Leveraging Investments for PPH Impact Project

R10-2-22-e: Cost Extension for the Project “Health for all: Increasing access to HIV, TB and Hepatitis C treatment through effective use of TRIPS flexibilities”

R9-2022-e: Cost Extension for the Project “Expanding the use of TRIPS flexibilities to promote affordable access to medicines”

R8-2022-e: Cost Extension for the Project “Use of TRIPS flexibilities to increase affordability of treatment for HIV, tuberculosis and hepatitis C virus in middle-income countries”

R7-2022-e: Additional contribution from Germany

R6-2022-e: Unitaid support to PAHO for enabling activities relating to the project CUIDA Chagas

R5-2022-e: Cost Extension for the Project: ‘Increasing Market and Public Health Outcomes through Scaling Up Affordable Access Models of Short Course Preventive Therapy for TB’ (IMPAACT4TB)

R4-2022-e: Additional contribution from Japan

R3-2022-e: Further investments to enhance access to COVID-19 therapeutics and ancillary products in low- and middle-income countries

R2-2021-e: Additional contribution from Spain

R1-2022-e: Additional contribution from Norway

2021

R32-2021-e: Cost Extension for the Project ‘Preventing deaths from cervical cancer by catalysing the use of optimal screening tests and treatment devices’

R31-2021-e: Cost Extension for the Project ‘Unitaid support to WHO prequalification of medicines and in vitro diagnostics, and to the WHO collaborative procedure for registration’

R30-2021-e: Malaria Vaccine Pilot Implementation Program – Phase 2

R29-2021-e: Additional contribution from Italy

R28-2021-e: Cost Extension for the Project ‘Preparedness for the Rollout of Effective HIV Prevention among Key Affected Populations in Brazil, Peru and Mexico’

R27-2021-e: Cost Extension for the Project ‘Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women’

R26-2021-e: Cost Extension for the Project: ‘Accelerating Demand for HIV Self- Testing (HIVST) Among Young People’

R25-2021-e: Calendar of Board and Committee meetings for 2022

R24-2021-e: Costed Extension of the Self-Testing AfRica (STAR) Initiative

R23-2021-e: Second extension of duration of ongoing Support for measures in the global response to COVID-19

R22-2021-e: Catalytic interventions to increase sustainable access to medical oxygen (MOXY) project

R21-2021-e: Building Reliable Integrated & Next Generation O2 Services (BRING O2) Project

R20-2021-e: Additional contributions from Canada, France and Germany

R19-2021-e: Cost Extension for the D2EFT Project

R18-2021-e: Go-ahead for the development of grant agreement packages on Accelerating tools to drive tuberculosis (TB) detection for proposed projects with FIND, the Global Alliance for Diagnostics, and Liverpool School of Tropical Medicine, UK

R17-2021-e: Increase to the budget for the COVID-19 Emergency Oxygen Response with funding authorizations for CHAI and the WHO Health Emergencies Programme

R16-2021-e: Funding authorization for the ‘Africa, Asia, Americas COVID-19 Preparedness’ (3ACP) project

R15-2021-e: Funding authorization for the ‘Catalyzing COVID-19 ACTION’ project

R14-2021-e: Funding authorization for the ‘Enhancing access to COVID-19 test, isolate, care and treat interventions within healthcare systems in LMICs’ project

R13-2021-e: Funding authorization for the IMPAACT4C19 project

R12-2021-e: The SP-IPTi+ Project

R11-2021-e: Postpartum Hemorrhage Proposals

R10-2021-e: Funding authorisation for the CHAI COVID-19 Oxygen Technical Cooperation project

R9-2021-e: Additional contribution from the Wellcome Trust for investment within the ACT-A Oxygen Emergency Response

R8-2021-e: MMV VivAction Project

R7-2021-e: Additional contribution from Portugal

R6-2021-e: “Towards the elimination of congenital infection in Chagas Disease in Latin America (CUIDA Chagas)” Project

R5-2021-e: Investments within the ACT-A Oxygen Emergency Response

R4-2021-e: Additional contribution from Japan

R3-2021-e: Extension of duration of ongoing support for measures in the global response to COVID-19

R2-2021-e: Extension for the Project ‘Preparedness for the Rollout of Effective HIV Prevention among Key Affected Populations

R1-2021-e: Additional contributions from Canada and Norway

2020

R19-2020-e: Extension and amendment of MMV Supply Grant to include an output on IPTi

R18-2020-e: Additional contribution from the Republic of Korea

R17-2020-e: Costed Extension of the Self-Testing AfRica (STAR) Initiative

R16-2020-e: Unitaid support to the Medicines Patent Pool Foundation during Phase III (2021-2025)

R15-2020-e: Partnership between Unitaid and FIND to co-fund investments in “Driving equitable access to fit-for-purpose antigen-detecting rapid diagnostic tests for COVID-19”

R14-2020-e: Additional contribution from France

R13-2020-e: Funding authorisation for the “CHAI COVID-19 Testing Transformation” Initiative through a cost extension of the project: “Preventing Deaths from Cervical Cancer by Catalysing the use of Optimal Screening Tests and Treatment Devices”

R12-2020-e: Cost Extension for the Project ‘Accelerating Patient Access to Optimal Antiretrovirals and Relevant Health Products’

R11-2020-e: Funding authorisation for the “ANTICOV” project

R10-2020-e: Calendar of Board and Committee meetings for 2020 and 2021

R9-2020-e: Go-ahead for the development of a grant agreement package on Intermittent Preventive Treatment in infants for a proposed project with Population Services International

R8-2020-e: Go-ahead for the development of grant agreement package on Towards the elimination of congenital infection in Chagas Disease through better tools for diagnosis and treatment with Fiotec

R7-2020-e: Funding of new grantees in the response to COVID-19

R6-2020-e: Cost Extension for three ARV Clinical Trial Projects (“TRIO”)

R5-2020-e: Support for measures for the global response to COVID-19

R4-2020-e: Long-acting injectable formulation of ivermectin as a new vector control tool to reduce malaria transmission (IMPACT)

R3-2020-e: Self-Testing AfRica (STAR) Initiative Extension

R2-2020-e: Global long-acting drug combination development (GLAD) project: transformation of oral short-acting TLD to long-acting injectable products

R1-2020-e: Long acting pipeline to establish medicines for malaria, tuberculosis and hepatitis C virus with infrastructure for sustainable translational capacity (LONGEVITY) Project

2019

R19-2019-e: “Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy (SUCCESS)” Project

R17-2019-e: Better Access to Treatment for Pediatric MDR-TB (BENEFIT Kids) Project

R16-2019-e: Radical Cure Vivax Malaria (RADICAL) project with Malaria Consortium

R15-2019-e: Go-ahead for the development of grant agreement package on Better tools for the diagnosis and treatment of Plasmodium vivax malaria for proposed project with MMV

R14-2019-e: Go-ahead for the development of grant agreement packages on Accelerating impact of long-acting technologies in low- and middle income countries for proposed projects with MedinCell, University of Liverpool, and University of Washington

R13-2019-e: Amendment to WHO Enabler Grant

R12-2019-e: “Adherence Support Coalition to End TB” Project

R11-2019-e: “Tools for Integrated Management of Childhood Illness -TIMCI” Project

R10-2019-e: “OPTimisation de L’Identification des Fievres A Risque chez l’Enfant – OPTIFARE” Project

R9-2019-e: Terms of Reference for Board Vice-Chair

R8-2019-e: “Rapid, comprehensive targeted gene sequencing solution for drug-resistant TB diagnosis in LMICs” Project

R7-2019-e: “Preventing Deaths from Cervical Cancer by Catalysing the use of Optimal Screening Tests and Treatment Devices” Project

R6-2019-e: Extension of terms of office for Chairs and Vice-Chairs of the Standing Committees of the Board

R5-2019-e: Contribution from Japan for 2019

R4-2019-e: “Broad One Health Endectocide-based Malaria Intervention in Africa” (BOHEMIA) Project

R3-2019-e: “Advancing Spatial Repellents for Vector-borne Disease Control” Project

R2-2019-e: Terms of Reference for Board Chair

R1-2019-e: Accelerating Demand for HIV Self-Testing through a Human Centered Design Challenge Fund and Campaign

2018

R22-2018-e: “Accelerating Patient Access to Optimal Antiretrovirals and Relevant Health Products” Project

R21-2018-e: Second Costed Extension of the HIV/HCV Drug Affordability Project

R20-2018-e: Unitaid support to WHO prequalification of medicines and in vitro diagnostics, and to the WHO collaborative procedure for registration (2019-2021)

R19-2018-e: Go-ahead for the development of grant agreement packages on better tools for integrated management of childhood fever for proposed projects with PATH and ALIMA

R18-2018-e: Go-ahead for the development of grant agreement packages on preventing deaths from cervical cancer for proposed projects with Clinton Health Access Initiative (CHAI) and Expertise France

R17-2018-e: Additional Contribution from the United Kingdom

R16-2018-e: Terms of Reference of the Unitaid 2017-2021 Midterm Strategy Review

R15-2018-e: Go ahead for the development of grant agreement packages for proposed projects with Koninklijke Nederlandse Centrale Vereniging tot bestrijding der Tuberculose (KNCV), FIND, Celltrion, Inc. and Stellenbosch University for the treatment of tuberculosis and its drug-resistant strains

R14-2018-e: Expand New Drug Markets for TB (endTB) Project

R13-2018-e: Go ahead for the development of an agreement with EJAF to co-finance a Demand Creation Campaign and Challenge Fund for HIVST

R12-2018-e: Catalytic Long Lasting Insecticidal Nets (LLIN) Initiative

R11-2018-e: Expanding the use of TRIPS flexibilities to promote affordable access to medicines

R10-2018-e: Use of TRIPS flexibilities to increase affordability of treatment for HIV, tuberculosis and hepatitis C virus in middle-income countries

R9-2018-e: Calendar of Board and Committee meetings 2019

R8-2018-e: Appointment of Interim Board Chair

R7-2018-e: Health for all: Increasing access to HIV, TB and Hepatitis C treatment through effective use of TRIPS flexibilities

R6-2018-e: Go-ahead for the development of a grant agreement package for the extension and expansion of the Expand New Drug Markets for TB Project

R5-2018-e: ATLAS – Autotest, libre d’accéder à la connaissance de son statut VIH

R4-2018-e: Accelerating Demand for HIV Self-Testing (HIVST) Among Young People

R3-2018-e: Go ahead for the development of grant agreement package with the Innovative Vector Control Consortium (lVCC) under the Area for Intervention “Accelerating the adoption of innovative vector control tools”

R2-2018-e: Calendar of Board and Committee meetings 2018

R1-2018-e: Go ahead for the development of grant agreement packages on new tools for vector control for proposed projects with Barcelona Institute for Global Health (ISGlobal), University of Notre Dame and Wageningen University

2017

R23-2017-e: Costed Extension of the HIV /HCV Drug Affordability project

R22-2017-e: Go ahead for the development of the International Treatment Preparedness Coalition (lTPC), South Centre (SC) and Third World Network (TWN) grant packages under the Area for Intervention “Supporting the use of TRIPS flexibilities”

R21-2017-e: Integrating PrEP into Comprehensive Services for Adolescent Girls and Young Women in South Africa

R20-2017-e: Catalyzing pediatric TB innovation (CAP TB)

R19-2017-e: WHO TB Enabler Grant

R18-2017-e: Increase to budget ceilings for the RAS and TIPTOP Projects

R17-2017-e: WHO-HTM Enabler malaria sub-grant

R16-2017-e: Indemnification of WHO with respect to claims under a Bank of England Mandate Letter

R15-2017-e: Strengthening paediatric TB services for enhanced early detection (TB SPEED)

R14-2017-e: IMPAACT4TB Increasing market and public health outcomes through scaling up affordable access models of short course preventive therapy for TB

R13-2017-e: Amended Calendar of Board and Committee meetings dates for the fourth quarter of 2017

R12-2017-e: No cost extension of the Project “Market entry of an improved solid protease inhibitor-based first line antiretroviral combination therapy for infants and young children with HIV/AIDS” by DNDi

R11-2017-e: Costed extension of the ACCESS-SMC project

R10-2017-e: Go ahead for the development of Solthis and MTV Staying Alive Foundation (SAF) proposals on HIV self-testing

R9-2017-e: Amendment to Workstream 2 (PrEP and HIV Self-Testing) of the WHO HTM Enabler HIV/HCV sub-grant

R8-2017-e: Self-Testing AfRica (STAR) Initiative

R7-2017-e: Preparedness for the rollout of effective HIV prevention among Key affected Populations in Brazil, Peru and Mexico

R6-2017-e: Costed extension of Unitaid project support to WHO Prequalification of Medicines and Diagnostics

R5-2017-e: Malaria Vaccine Pilot Implementation Programme

R4-2017-e: Medicines for Malaria Venture Supply Side Grant

R3-2017-e: No cost extension of MSF Project “Implementation of CD4 and Viral Load Testing in Decentralised, Remote and Resource-Limited Settings

R2-2017-e: TIPTOP – Transforming IPT for Optimal Pregnancy

R1-2017-e: Rectal Artesunate – RAS Project

2016

R18-2016-e: Go-ahead for the Aurum “IMPAACT4TB” proposal

R17-2016-e: Go-ahead for the development of paediatric TB project proposals

R16-2016-e: Safer, more robust and less expensive antiretroviral first-line therapy (ADVANCE trial)

R15-2016-e: A randomised trial to compare dolutegravir+darunavir/r versu recommended standard of care antiretroviral regimens in patients with HIV infection who have failed recommended first-line therapy

R14-2016-e: DolPHIN2: Dolutegravir in Pregnant HIV mothers and Neonates

R13-2016-e: Accelerating access and integration of innovative point-of-care HIV technologies in national diagnostic programs – Phase 2b

R12-2016-e: E-market place for the procurement of public health commodities (wambo.org)

R11-2016-e: Go-ahead for the development of project proposal

R10-2016-e: P3: Private Sector Provision of PrEP Sep 2016

R9-2016-e: Enabling Scale-up of PrEP and Linkage to Testing among sexually active older adolescents with substantial HIV risk

R8-2016-e: Unlocking the Hepatitis C Diagnostics and Treatment Market Sep 2016

R7-2016-e: WHO HTM Enabler sub-grant HIV/HCV

R6-2016-e: Accelerating Patient Access to Optimal Antiretrovirals

R4-2016-e: Go-ahead for the development of project proposals

R3-2016-e: Enabling access to first-line antiretroviral treatment in low-income countries

R2-2016-e: Go-ahead for the development of project proposaI for the “E-marketpIace”

R1-2016-e: Market intervention to accelerate uptake of new vector control tools

R1-2015-e: Calendar of Unitaid Board meetings for 2015

2015

R2-2015-e: Calendar of Unitaid board meetings for 2015

R3-2015-e: Go-ahead for the development of project proposals

2014

R3-2014-e: Stimulating and shaping the market for HIV self-testing in Africa: two-tier demonstration and evaluation of accuracy and linkage in 4 countries

R2-2014-e: Unitaid revised project budget 2014

R1-2014-e: Unitaid Key Performance Indicators 2013-2016

2013

R6-2013-e: Endorsement of Unitaid KPI Report 2012

R5-2013-e: Endorsement of Unitaid Strategy 2013-2016

R4-2013-e: MDR-TB Strategic Rotating Stockpile Project_No-cost extension

R3-2013-e: MDR-TB Scale-up Initiative Project_No-cost Extension

R1- 2013-e: Additional Funding for AMFm Transition Year 2013